The diagnostic approach to acute myocardial infarction (AMI) is still one of the most
challenging and controversial medical issues. Although the measurement of cardiospecific …

Publisher Summary The chapter presents a general overview of the clinical and analytical
issues pertaining to the albumin–cobalt binding (ACB) test that measures ischemia-modified …

We studied the role of ischemia-modified albumin (IMA) with standard biomarkers
(myoglobin, creatine kinase-MB [CK-MB], troponin I [TnI]) in assessment of 200 patients with …

Objective: Ischemia-modified albumin (IMA®) is a novel marker for assessing cardiac
ischaemia. We assessed the relationship between total albumin concentrations and IMA in …

BACKGROUND: Existing cardiac markers are not sensitive for reversible myocardial
ischemia. Ischemia modified albumin (IMA) has recently been shown to be an early and …

Ischemia modified albumin (IMA), as measured using the albumin cobalt binding test, is
currently the most promising biomarker for early detection of ischemia before the onset of …

The diagnosis of cardiac ischemia remains a challenge in contemporary emergency
medicine. A blood-borne biomarker is an attractive alternative to cardiac imaging or stress …

Ischemia-modified albumin (IMA) has been proposed as a biological marker of myocardial
ischemia (1, 2). Exposure to ischemic myocardium modifies circulating albumin at its NH2 …

The albumin cobalt-binding test (Ischemia Technologies), which measures the concentration
of ischemia-modified albumin (IMA), has been cleared by the US Food and Drug …

The purpose of this study was to validate the Albumin Cobalt Binding (ACB®) assay at the
Seattle Veterans Affairs (VA) Hospital to determine if it would provide an earlier rule-out of …